A citation-based method for searching scientific literature

Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li. Cancer Discov 2020
Times Cited: 98



J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon, M Van den Heuvel, J Neal, N Peled, M Früh, T L Ng, V Gounant, S Popat, J Diebold, J Sabari, V W Zhu, S I Rothschild, P Bironzo, A Martinez-Marti, A Curioni-Fontecedro, R Rosell, M Lattuca-Truc, M Wiesweg, B Besse, B Solomon, F Barlesi, R D Schouten, H Wakelee, D R Camidge, G Zalcman, S Novello, S I Ou, J Milia, O Gautschi. Ann Oncol 2019
Times Cited: 373




List of shared articles



Times cited

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Shuyi Cen, Zhen Liu, Hongming Pan, Weidong Han. Biochim Biophys Acta Rev Cancer 2021
2


HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy.
Ioannis A Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N Syrigos. Pharmaceuticals (Basel) 2021
0

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.
Mihaela Aldea, Fabrice Andre, Aurelien Marabelle, Semih Dogan, Fabrice Barlesi, Jean-Charles Soria. Cancer Discov 2021
19


Consensus for HER2 alterations testing in non-small-cell lung cancer.
S Ren, J Wang, J Ying, T Mitsudomi, D H Lee, Z Wang, Q Chu, P C Mack, Y Cheng, J Duan,[...]. ESMO Open 2022
0

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han,[...]. Cancer Immunol Immunother 2022
1

Overcoming therapy resistance in EGFR-mutant lung cancer.
Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters. Nat Cancer 2021
25

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
7



Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
81


NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
166

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
43

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni. Crit Rev Oncol Hematol 2020
31